BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 28498280)

  • 1. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver.
    Yang Z; Klimstra DS; Hruban RH; Tang LH
    Am J Surg Pathol; 2017 Jul; 41(7):915-922. PubMed ID: 28498280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of SATB2, ISL1, and TTF1 to differentiate rectal from other gastrointestinal and lung well-differentiated neuroendocrine tumors.
    Zhao LH; Chen C; Mao CY; Xiao H; Fu P; Xiao HL; Wang G
    Pathol Res Pract; 2019 Jul; 215(7):152448. PubMed ID: 31133441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms.
    Chan ES; Alexander J; Swanson PE; Jain D; Yeh MM
    Am J Surg Pathol; 2012 May; 36(5):737-43. PubMed ID: 22498824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
    Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
    J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.
    Lin X; Saad RS; Luckasevic TM; Silverman JF; Liu Y
    Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):407-14. PubMed ID: 18091383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin.
    Koo J; Zhou X; Moschiano E; De Peralta-Venturina M; Mertens RB; Dhall D
    Endocr Pathol; 2013 Dec; 24(4):184-90. PubMed ID: 24037217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases.
    Schmitt AM; Riniker F; Anlauf M; Schmid S; Soltermann A; Moch H; Heitz PU; Klöppel G; Komminoth P; Perren A
    Am J Surg Pathol; 2008 Mar; 32(3):420-5. PubMed ID: 18300808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clusterin expression in gastrointestinal neuroendocrine tumours is highly correlated with location and is helpful in determining the origin of liver metastases.
    Mourra N; Scriva A; Mansiaux Y; Gozlan S; Bennis M; Balaton A
    Histopathology; 2014 Nov; 65(5):642-50. PubMed ID: 24807631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2.
    Hermann G; Konukiewitz B; Schmitt A; Perren A; Klöppel G
    Virchows Arch; 2011 Aug; 459(2):147-54. PubMed ID: 21739268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of TTF1, CDX2 and ISL1 in 74 poorly differentiated neuroendocrine carcinomas.
    Lee H; Fu Z; Koo BH; Sheehan CE; Young GQ; Lin J; Patil DT; Yang Z
    Ann Diagn Pathol; 2018 Dec; 37():30-34. PubMed ID: 30236546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.
    Yang Z; Tang LH; Klimstra DS
    Am J Surg Pathol; 2011 Jun; 35(6):853-60. PubMed ID: 21566513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin.
    Koo J; Mertens RB; Mirocha JM; Wang HL; Dhall D
    Mod Pathol; 2012 Jun; 25(6):893-901. PubMed ID: 22388755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fine needle aspiration cytology of hepatic metastases of neuroendocrine tumors: A 20-year retrospective, single institutional study.
    Saeed OAM; Cramer H; Wang X; Wu HH
    Diagn Cytopathol; 2018 Jan; 46(1):35-39. PubMed ID: 29076658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of PAX6 and PAX8 as immunohistochemical markers for pancreatic neuroendocrine tumors.
    Lai JP; Mertens RB; Mirocha J; Koo J; Venturina M; Chung F; Mendez AB; Kahn M; Dhall D
    Endocr Pathol; 2015 Mar; 26(1):54-62. PubMed ID: 25433656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of wireless capsule endoscopy (WCE) in the detection of occult primary neuroendocrine tumors.
    Furnari M; Buda A; Delconte G; Citterio D; Voiosu T; Ballardini G; Cavallaro F; Savarino E; Mazzaferro V; Meroni E
    J Gastrointestin Liver Dis; 2017 Jun; 26(2):151-156. PubMed ID: 28617885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
    Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
    Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors.
    Scott AT; Pelletier D; Maxwell JE; Sherman SK; Keck KJ; Li G; Dillon JS; O'Dorisio TM; Bellizzi AM; Howe JR
    Ann Surg Oncol; 2019 Aug; 26(8):2525-2532. PubMed ID: 31011904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cdx2 as a marker for neuroendocrine tumors of unknown primary sites.
    Erickson LA; Papouchado B; Dimashkieh H; Zhang S; Nakamura N; Lloyd RV
    Endocr Pathol; 2004; 15(3):247-52. PubMed ID: 15640551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
    J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.